All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What you need to know about keratopathy management with belamaf
Video series
BCMA-targeted agents for RRMM
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Evangelos Terpos, National and Kapodistrian University of Athens, Athens, GR. He discusses what you need to know about keratopathy management with belamaf.
Belamaf is an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) approved in the US and EU for the treatment of relapsed/refractory multiple myeloma (R/R MM). Terpos outlines a study investigating the relationships between corneal exam findings, best-corrected visual acuity (BCVA) changes, and patient-reported ocular symptoms in patients with R/R MM receiving belamaf.
Video series
BCMA-targeted agents for RRMM
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox